Images List Premium Download Classic

Cathepsin

Cathepsin-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Cathepsin-binding compounds bound to a carrier and their diagnostic use
J. Stefan Institute
March 29, 2018 - N°20180085479

The invention relates to cathepsin-binding compounds bound to a carrier comprising a diagnostic moiety, for use in the diagnosis of inflammatory diseases, and/or for use in the diagnosis of neoplastic diseases, wherein the cathepsin-binding compound binds to inflammatory cells of the tumour stroma. The invention also relates to cathepsin b-targeting compounds and cathepsin b-binding and liposome-binding compounds.
Biomarker panel for diagnosing cancer
Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts
March 22, 2018 - N°20180080937

The present invention pertains to a new method for the diagnosis, prognosis, stratification and/or monitoring of a therapy, of cancer in a patient. The method is based on the determination of the level of a panel of biomarkers selected from cea, areg, il-6, gdf-15, hgf-receptor, cxcl9, erbb4-her4, cxclio, flt3l, vegfr-2, cd69, cxcl5s, psa, emmprin, cathepsin-d, caspase-3, ...
Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
Immunobiochem Corporation
March 22, 2018 - N°20180078654

The present disclosure relates to conjugates, preferably, antibody-drug conjugates, directed against select non-transmembrane tumor antigens that are normally intracellular but can be secreted from cancer cells, such as human cathepsin d, and can be targeted in a way that enables the selective delivery of the conjugate to cancer cells. The design and mechanism of action disclosed enable the preferential delivery ...
Cathepsin Patent Pack
Download + patent application PDFs
Cathepsin Patent Applications
Download + Cathepsin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cathepsin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Astute Medical, Inc.
November 30, 2017 - N°20170343562

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of hyaluronic acid, ...
Protease inhibitors
November 23, 2017 - N°20170334867

Or a pharmaceutically acceptable salt, n-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin k, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.
Methods for treating pulmonary emphysema using substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of ...
September 21, 2017 - N°20170266160

And their use as inhibitors of cathepsin c, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase i activity, e. G. Respiratory diseases.
Cathepsin Patent Pack
Download + patent application PDFs
Cathepsin Patent Applications
Download + Cathepsin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cathepsin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Astute Medical, Inc.
September 07, 2017 - N°20170254816

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of cancer antigen ca 15-3, c-c motif chemokine 18, ...
Glycopeptide for contrast agent targeting cancer cells and contrast agent kit containing the same
Korea Institute Of Science And Technology
August 03, 2017 - N°20170216460

The present disclosure relates to a glycopeptide targeting cancer cells and a contrast agent kit containing the same. The glycopeptide is one wherein an azide reporting monosaccharide is bound to a substrate peptide. As the substrate peptide is specifically cleaved by cathepsin b in cancer cells, an azide reporting monosaccharide is expressed onto the cell surface via metabolic glycoengineering, thereby ...
Method for monitoring cathepsin s inhibition
July 06, 2017 - N°20170192000

C) correlating li p10 peptide level in white blood cells to cathepsin s inhibitor dose, wherein a cathepsin s inhibitor leads to increased level of li p10 peptide in the white blood cells.
Protease inhibitors
June 15, 2017 - N°20170166538

Or a pharmaceutically acceptable salt, n-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin k, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases:
Hydroxystatin derivatives for the treatment of arthrosis
Merck Patent Gmbh
March 23, 2017 - N°20170081361

The present invention relates to compounds of the formula (i) and in particular to medicaments comprising at least one compound of the formula (i) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions in the triggering of which cathepsin d is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic ...
Novel substituted spirocycles
March 16, 2017 - N°20170073352

Wherein a and cy have one of the meanings as indicated in the specification and their use as inhibitors of cathepsin c, pharmaceutical compositions containing the same and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase i activity, e. G. Respiratory diseases.
Formulations for cathepsin k inhibitors
February 23, 2017 - N°20170049741

The instant invention relates to pharmaceutical compositions containing cathespin k inhibitors. Also disclosed are processes for making said pharmaceutical compositions.
Cathepsin Patent Pack
Download + patent application PDFs
Cathepsin Patent Applications
Download + Cathepsin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cathepsin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel assay for early detection of a disease using a magnetic nanoparticle biosensor
Alfaisal University
February 09, 2017 - N°20170037450

A multiplex hand-held diagnostic biosensor, using two inflammatory salivary biomarkers, human neutrophil elastase (hne) and cathepsin-g, was constructed made to potentially detect periodontitis at an early stage is described. The use of magnetic nanoparticle biosensor method used as a device was based on the measurement of proteolytic activity using specific proteases probes. The magnetic nanoparticle biosensor device is capable of ...
Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
Mesoblast International Sàrl
December 29, 2016 - N°20160375100

The present invention features mutant stromal cell derived factor-1 (sdf-1) peptides that have been mutated to make them resistant to digestion by, for example, the proteases dipeptidyl peptidase iv (dppiv), matrix metalloproteinase-2 (mmp-2), matrix metalloproteinase-9 (mmp-9), leukocyte elastase, cathepsin g, carboxypeptidase m, and carboxypeptidase n, but which retain chemoattractant activity.
Compositions and methods for inhibition of cathepsins
December 22, 2016 - N°20160368869

This invention is directed to compound of formula i and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin k or cathepsin l, will be therapeutically useful.
Furo[3, 2-b] pyrr0l-3-ones as cathespin s inhibitors
December 15, 2016 - N°20160361295

Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.
Cathepsin cysteine protease inhibitors
Merck Sharp & Dohme Corp.
December 08, 2016 - N°20160355502

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins k, l, s and b. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity
November 17, 2016 - N°20160333051

Wherein z is a chain of 11 α-amino acid residues which, depending on their positions in the chain (counted starting from the n-terminal amino acid) are gly, or pro, or pro(4nhcophe), or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property ...
Cathepsin cysteine protease inhibitors
Merck Sharp & Dohme Corp.
August 25, 2016 - N°20160244417

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins k, l, s and b. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
August 18, 2016 - N°20160237060

Wherein ht, g, r10, r30, r40, r50 and r60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin a, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the ...
Loading